Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Autolus Therapeutics plc (NASDAQ:AUTL) climbed $8 (47%) to $25 its first day
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury